5-Fluorouracil, mitomycin-C, and polysaccharide-K adjuvant chemoimmunotherapy for locally advanced gastric cancer: The prognostic significance of frequent perineural invasion

Hepato-Gastroenterology

Volumn 54, Issue 73, 2007, Pages 290-297

  Choi, Jin Hyuk ^a   Kim, Young Bae ^a   Lim, Ho Yeong ^a   Joon, Seong Park ^a   Hugh, Chul Kim ^a   Yong, Kwan Cho ^a   Sang, Wook Han ^a   Myung, Wook Kim ^a   Hee, Jae Joo ^a  

^a Ajou University School of Medicine   (South Korea)

Author keywords

Chemoimmunotherapy; Gastric cancer; Perineural invasion; Prognosis

Indexed keywords

DOXORUBICIN; FLUOROURACIL; KRESTIN; MITOMYCIN C; PICIBANIL;

ADULT; ARTICLE; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOTHERAPY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; SKIN NECROSIS; STOMACH CANCER; UNSPECIFIED SIDE EFFECT;

ADENOCARCINOMA; ADULT; ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; FEMALE; FLUOROURACIL; HUMANS; IMMUNOTHERAPY; MALE; MIDDLE AGED; MITOMYCIN; MULTIVARIATE ANALYSIS; NEOPLASM INVASIVENESS; PERIPHERAL NERVES; PROGNOSIS; STOMACH NEOPLASMS;

EID: 34047188453     PISSN: 01726390     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Fuchs CS, Mayer RJ: Gastric carcinoma. N Engl J Med 1995; 333:32-41.
2. Shin HR, Ahn Y-O, Bae J-M, Shin M-H, Lee D-H, Lee C-Won, Ohrr H, Ahn D-H, Ferlay J, Parkin DM, Oh D-K, Park J-G: Cancer Incidence in Korea. Cancer Res Treat 2002; 34:405-408.
3. Noguchi Y, Imada T, Matsumoto A, Coit DG, Brennan MF: Radical surgery for gastric cancer: a review of the Japanese experience. Cancer 1989; 64:2053-2062.
4. Macdonald JS: Adjuvant therapy for gastric cancer. Semin Oncol 2003; 30(4 Suppl 11):19-25.
5. Kelsen DP: Adjuvant and neoadjuvant therapy for gastric cancer. Semin Oncol 1996; 23:379-389.
6. Krook JE, O'Connell MJ, Wieand HS, Beart RW Jr, Leigh JE, Kugler JW, Foley JF, Pfeifle DM, Twito DI: A prospective, randomized evaluation of intensive-course 5-fluorouracil plus doxorubicin as surgical adjuvant chemotherapy for resected gastric cancer. Cancer 1991; 67:2454-2458.
7. Lise M, Nitti D, Marchet A, Sahmoud T, Buyse M, Duez N, Fiorentino M, Santos JGD, Labianca R, Rougier P, Gignoux M: Final results of a phase III clinical trial of adjuvant chemotherapy with the modified fluorouracil, doxorubicin, and mitomycin regimen in resectable gastric cancer. J Clin Oncol 1995; 13:2757-2763.
8. Macdonald JS, Fleming TR, Peterson RF, Berenberg JL, McClure S, Chapman RA, Eyre HJ, Solanki D, Cruz AB Jr, Gagliano R, Estes NC, Tangen CM, Rivkin S: Adjuvant chemotherapy with 5-FU, adriamycin, and mitomycin-C (FAM) versus surgery alone for patients with locally advanced gastric adenocarcinoma: a Southwest Oncology Group Study. Ann Surg Oncol 1995; 2:488-494.
9. Nakajima T, Fukami A, Ohashi I, Kajitani T: Long-term follow-up study of gastric cancer patients treated with surgery and adjuvant chemotherapy with mitomycin C. Int J Clin Pharmacol Biopharm 1978; 16:209-216.
10. Grau JJ, Estape J, Alcobendas F, Pera C, Daniels M, Teres J: Positive results of adjuvant mitomycin-C in resected gastric cancer: a randomised trial on 134 patients. Eur J Cancer 1993; 29A:340-342.
11. Cirera L, Balil A, Batiste-Alentorn E, Tusquets I, Cardona T, Arcusa A, Jolis L, Saigi E, Guasch I, Badia A, Boleda M: Randomized clinical trial of adjuvant mitomycin plus tegafur in patients with resected stage III gastric cancer. J Clin Oncol 1999; 17:3810-3815.
12. Hermans J, Bonenkamp JJ, Boon MC, Bunt AMG, Ohyama S, Sasako M, Van de Velde CJH: Adjuvant therapy after curative resection for gastric cancer: meta-analysis of randomized trials. J Clin Oncol 1993; 11:1441-1447.
13. Hermans J, Bonenkamp JJ: In reply. J Clin Oncol 1994; 12:879-880. (Letter)
14. Earle CC, Maroun JA: Adjuvant chemotherapy after curative resection for gastric cancer in non-Asian patients: revisiting a meta-analysis of randomised trials. Eur J Cancer 1999; 35:1059-1064.
15. Mari E, Floriani I, Tinazzi A, Buda A, Belfiglio M, Valentini M, Cascinu S, Barni S, Labianca R, Torri V: Efficacy of adjuvant chemotherapy after curative resection for gastric cancer: a meta-analysis of published randomised trials. a study of the GISCAD (Gruppo Italiano per lo Studio dei Carcinomi dell'Apparato Digerente). Ann Oncol 2000; 11:837-843.
16. Panzini I, Gianni L, Fattori PP, Tassinari D, Imola M, Fabbri P, Arcangeli V, Drudi G, Canuti D, Fochessati F, Ravaioli A: Adjuvant chemotherapy in gastric cancer: a meta-analysis of randomized trials and a comparison with previous meta-analyses. Tumori 2002; 88:21-27.
17. Macdonald JS, Smalley SR, Benedetti J, Hundahl SA, Estes NC, Stemmermann GN, Haller DG, Ajani JA, Gunderson LL, Jessup JM, Martenson JA: Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 2001; 345:725-730.
18. Youn JK, Kim BS, Min JS, Lee KS, Choi HJ, Lee YB, Lee DW, Park IS, Roh JK, Chung JB: Adjuvant treatment of operable stomach cancer with polyadenylic polyuridylic acid in addition to chemotherapeutic agents: a preliminary report. Int J Immunopharmacol 1990; 12:289-295.
19. Kim S-Y, Park HC, Yoon C, Yoon HJ, Choi YM, Cho KS: OK-432 and 5-fluorouracil, doxorubicin, and mitomycin C (FAM-P) versus FAM chemotherapy in patients with curatively resected gastric carcinoma: a randomized phase III trial. Cancer 1998; 83:2054-2059.
20. Jeung HC, Rha SY, Noh SH, Min JS, Kim BS, Chung HC: Adjuvant 5-fluorouracil plus doxorubicin in D2-3 resected gastric carcinoma: 15-year experience at a single institute. Cancer 2001; 91:2016-2025.
21. Chang HM, Jung KH, Kim TY, Kim WS, Yang HK, Lee KU, Choe KJ, Heo DS, Bang YJ, Kim NK: A phase III randomized trial of 5-fluorouracil, doxorubicin, and mitomycin C versus 5-fluorouracil and mitomycin C versus 5-fluorouracil alone in curatively resected gastric cancer. Ann Oncol 2002; 13:1779-1785.
22. Kim J-P, Kwon O J, Oh ST, Yang HK: Results of surgery on 6589 gastric cancer patients and immunochemosurgery as the best treatment of advanced gastric cancer. Ann Surg 1992; 216:269-279.
23. Nakazato H, Koike A, Saji S, Ogawa N, Sakamoto J: Efficacy of immunochemotherapy as adjuvant treatment after curative resection of gastric cancer. Lancet 1994; 343:1122-1126.
24. Sakamoto J, Teramukai S, Nakazato H, Sato Y, Uchino J, Taguchi T, Ryoma Y, Ohashi Y: Efficacy of adjuvant immunochemotherapy with OK-432 for patients with curatively resected gastric cancer: a meta-analysis of centrally randomized controlled clinical trials. J Immunother 2002; 25:405-412.
25. American Joint Committee on Cancer: AJCC cancer staging manual, 6th Edition. New York: Springer, 2002; pp. 167-177.
26. Japanese Research Society for Gastric Cancer: The general rules for the gastric cancer study in surgery and pathology. Jpn J Surg 1981; 11:127-139.
27. Choi J-H, Lim H-Y, Nam DK, Kim HS, Cho DY, Yi JW, Kim HC, Cho YK, Kim MW, Joo HJ, Lee KB, Kim KB: Expression of thymidylate synthase in gastric cancer patients treated with 5-fluorouracil and doxorubicin-based adjuvant chemotherapy after curative resection. Br J Cancer 2001; 84:186-192.
28. Choi JH, Lim HY, Joo HJ, Kim HS, Yi JW, Kim HC, Cho YK, Kim MW, Lee KB: Expression of multidrug resistance-associated protein1, P-glycoprotein, and thymidylate synthase in gastric cancer patients treated with 5-fluorouracil and doxorubicin-based adjuvant chemotherapy after curative resection. Br J Cancer 2002; 86:1578-1585.
29. Kaplan EL, Meier P: Non-parametric estimation from incomplete observations. J Am Statist Assoc 1958; 53:457-481.
30. Cox DR: Regression models and life tables. J R Statist Soc 1972; 34:187-220.
31. Kim JP, Lee JH, Kim SJ, Yu HJ, Yang HK: Clinicopathologic characteristics and prognostic factors in 10 783 patients with gastric cancer. Gastric Cancer 1998; 1:125-133.
32. Kitamura K, Yamaguchi T, Sawai K, Nishida S, Yamamoto K, Okamoto K, Taniguchi H, Hagiwara A, Takahashi T: Chronologic changes in the clinicopathologic findings and survival of gastric cancer patients. J Clin Oncol 1997; 15:3471-3480.
33. Setala L, Lipponen P, Kosma VM, Marin S, Eskelinen M, Syrjanen K, Alhava E: Nuclear morphometry as a predictor of disease outcome in gastric cancer. J Pathol 1997; 181:46-50.
34. Lee HS, Lee HK, Kim HS, Yang HK, Kim WH: Tumour suppressor gene expression correlates with gastric cancer prognosis. J Pathol 2003; 200:39-46.
35. Becker KF, Keller G, Hoefler H: The use of molecular biology in diagnosis and prognosis of gastric cancer. Surg Oncol 2000; 9:5-11.
36. Hanna W: Testing for HER2 status. Oncology 2001; 61(Suppl 2):22-30.
37. Tanaka A, Watanabe T, Okuno K, Yasutomi M: Perineural invasion as a predictor of recurrence of gastric cancer. Cancer 1994; 73:550-555.
38. Tanaka A, Yoshikawa H, Okuno K, Yasutomi M: The importance of neural invasion (NI) as a prognostic factor in diffuse invasive gastric cancer. Surg Today 1997; 27:692-695.
39. Duraker N, Sisman S, Can G: The significance of perineural invasion as a prognostic factor in patients with gastric carcinoma. Surg Today 2003; 33:95-100.
40. Park SH, Kim DY, Heo JS, Lim DH, Park CK, Lee KW, Choi SH, Sohn TS, Kim S, Noh JH, Kim YI, Park JO, Kim K, Kim WS, Jung CW, Im YH, Lee MH, Park K, Park CH, Kang WK: Postoperative chemoradiotherapy for gastric cancer. Ann Oncol 2002; 14:1373-1377.